Dyadic receives last installment in $10 million payment from Codexis for enzyme production system

In Florida, Dyadic filed an SEC 8-K form confirming that the company has received the final installment in $10 million in upfront payments from Codexis for a license to utilize “the use of Dyadic’s C1 expression system for large-scale production of enzymes in certain fields including biofuels and chemical and pharmaceutical intermediate production.” The original agreement between Codexis and Dyadic was signed last November but was subject to performance criteria.

Free Subscription to the Daily Biofuels Digest e-newsletter

Related Stories

Enzyme, gene expression leader Dyadic files suit against legal counsel

In Florida, upheaval continues at enzyme biotechnology company Dyadic. Founder and CEO Mark Emelfarb, who regained control of the company last summer after a proxy fight, has filed suit against Ern...

Codexis licenses biomanufacturing technology for $10 million, to improve enzyme production cycle time

In Florida, Dyadic International announced that it has licensed its biomanufacturing technology to Codexis for $10 million. Codexis said that it would use the technology in conjunction with its synthe...

Dyadic says it has received “generally recognized as safe” notice from FDA for enzyme platform

In Florida, Dyadic International said it had received a generally recognized as safe ("GRAS") , notice from the FDA for cellulase enzyme preparation derived from a genetically modified strain of the c...

Enzyme systems developer Dyadic settles dispute with SEC

In Florida, Dyadic announced a settlement with the SEC over charges of violations to the Securities and Exchange Act. Under the terms of the settlement, Dyadic did not admit or deny the SEC finding...

Shell purchases stake in Codexis, an enzyme manufacturer for cellulosic ethanol

Shell has purchased an undisclosed stake in stake in Codexis, a company which manufactures enzymes for the cellulosic ethanol production process. Codexis executives said that they expect to build a co...

FDA approves Syngenta’s new corn seed for bulk trial; first seed to contain the vital corn amylase enzyme

In Washington, the FDA approved bulk trials of a new corn seed from Syngenta which contains the corn amylase enzyme, after positive results from pilot trials. The Anglo-Swiss group company said that i...